DK0936913T4 - Oralt farmaceutisk præparat indeholdende ibandronat - Google Patents

Oralt farmaceutisk præparat indeholdende ibandronat

Info

Publication number
DK0936913T4
DK0936913T4 DK97918146.8T DK97918146T DK0936913T4 DK 0936913 T4 DK0936913 T4 DK 0936913T4 DK 97918146 T DK97918146 T DK 97918146T DK 0936913 T4 DK0936913 T4 DK 0936913T4
Authority
DK
Denmark
Prior art keywords
pharmaceutical preparation
preparation containing
oral pharmaceutical
containing ibandronate
ibandronate
Prior art date
Application number
DK97918146.8T
Other languages
Danish (da)
English (en)
Other versions
DK0936913T3 (da
Inventor
Joern Moeckel
Rolf-Dieter Gabel
Heinrich Woog
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7791961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0936913(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Application granted granted Critical
Publication of DK0936913T3 publication Critical patent/DK0936913T3/da
Publication of DK0936913T4 publication Critical patent/DK0936913T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK97918146.8T 1996-04-20 1997-04-21 Oralt farmaceutisk præparat indeholdende ibandronat DK0936913T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19615812A DE19615812A1 (de) 1996-04-20 1996-04-20 Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
PCT/EP1997/001940 WO1997039755A1 (de) 1996-04-20 1997-04-21 Orale pharmazeutische zubereitung enthaltend ibandronat

Publications (2)

Publication Number Publication Date
DK0936913T3 DK0936913T3 (da) 2008-10-20
DK0936913T4 true DK0936913T4 (da) 2012-11-19

Family

ID=7791961

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97918146.8T DK0936913T4 (da) 1996-04-20 1997-04-21 Oralt farmaceutisk præparat indeholdende ibandronat

Country Status (26)

Country Link
US (2) US6143326A (enExample)
EP (2) EP1658852B1 (enExample)
JP (2) JP5037746B2 (enExample)
CN (1) CN101152160A (enExample)
AR (2) AR006652A1 (enExample)
AT (1) ATE404207T1 (enExample)
AU (1) AU722516B2 (enExample)
BR (1) BR9708785A (enExample)
CA (1) CA2251886C (enExample)
CO (1) CO4820394A1 (enExample)
CZ (1) CZ297341B6 (enExample)
DE (2) DE19615812A1 (enExample)
DK (1) DK0936913T4 (enExample)
ES (1) ES2313735T5 (enExample)
HU (1) HU228389B1 (enExample)
IL (2) IL163930A0 (enExample)
NO (1) NO319162B1 (enExample)
NZ (1) NZ332314A (enExample)
PA (1) PA8427301A1 (enExample)
PL (2) PL191910B1 (enExample)
PT (1) PT936913E (enExample)
RU (1) RU2193881C2 (enExample)
SI (1) SI0936913T2 (enExample)
TR (1) TR199802108T2 (enExample)
WO (1) WO1997039755A1 (enExample)
ZA (1) ZA973331B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
RU2193880C2 (ru) * 1997-06-11 2002-12-10 Дзе Проктер Энд Гэмбл Компани Покрытая пленкой таблетка улучшенной безопасности для верхних отделов желудочно-кишечного тракта
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
AR024462A1 (es) * 1999-07-01 2002-10-02 Merck & Co Inc Tabletas farmaceuticas
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US6476006B2 (en) * 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
AU2001271055B2 (en) * 2000-07-17 2005-07-07 Astellas Pharma Inc. Pharmaceutical composition improved in peroral absorbability
JP2002332235A (ja) * 2001-02-01 2002-11-22 Riderway Corp 骨疾患治療用液体医薬組成物
AR034199A1 (es) * 2001-02-01 2004-02-04 Riderway Corp Composicion farmacologica liquida para el tratamiento de enfermedades oseas y procedimientos para su elaboracion
BR0209360A (pt) * 2001-05-02 2004-06-08 Novartis Ag Método de administração de bisfosfonatos por inalação no tratamento ou prevenção de reabsorção óssea e osteoporose
BR0206441A (pt) * 2001-12-19 2003-12-30 Astrazeneca Ab Composição de revestimento de pelìcula, revestimento de pelìcula cobrindo um núcleo farmacêutico, formulação farmacêutica de liberação modificada, e, processos para preparar uma composição de revestimento de pelìcula, um revestimento de pelìcula e uma formulação
NZ532994A (en) * 2001-12-21 2008-05-30 Procter & Gamble Method for the treatment of bone disorders using a bisphosphonate regimen, risedronate in particular
MXPA04008164A (es) 2002-02-21 2005-05-17 Biovail Lab Inc Formas de dosificacion de liberacion controlada.
CA2481142C (en) * 2002-05-10 2012-11-13 F.Hoffmann-La Roche Ag Bisphosphonic acids for the treatment and prevention of osteoporosis
GB0229258D0 (en) * 2002-12-16 2003-01-22 Boots Healthcare Int Ltd Medicinal compositions
NZ555514A (en) * 2002-12-20 2008-12-24 Hoffmann La Roche High dose ibandronate formulation
TR200300510A2 (tr) * 2003-04-18 2004-11-22 Sanovel �La� Sanay� Ve T�Caret A.�. Dağılan alendronat mikropartikül formülasyonu
RU2262923C2 (ru) * 2003-12-25 2005-10-27 Государственное образовательное учреждение высшего профессионального образования Курский государственный медицинский университет Министерства здравоохранения Российской Федерации Иммобилизованная форма доксорубицина
GB0403628D0 (en) * 2004-02-18 2004-03-24 Arrow Group Ltd Compression-coated tablets and the manufacture thereof
US20080286359A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US20080287400A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645460B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
WO2006039721A2 (en) * 2004-10-08 2006-04-13 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US20070191315A1 (en) * 2006-02-16 2007-08-16 Bengt Bergstrom Method for administering ibandronate
EP2001486A4 (en) * 2006-03-17 2010-12-29 Univ Illinois BIPHOSPHONATE COMPOUNDS AND CORRESPONDING METHODS
CN101495101B (zh) * 2006-07-25 2012-02-29 兴和株式会社 糖衣制剂及其制造方法
GB0616794D0 (en) 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
WO2009075601A1 (fr) * 2007-12-12 2009-06-18 Alexander Valerievich Melnik Moyen d'indication d'une éventuelle prédisposition de chats à une maladie (variantes) et procédé de détermination de troubles de la santé chez les chats
EP2210596A1 (en) 2009-01-22 2010-07-28 Laboratorios Liconsa, S.A. Pharmaceutical composition of ibandronate sodium salt or a hydrate thereof
CN103079596B (zh) * 2010-08-31 2015-08-19 东丽株式会社 药物固体制剂用的包衣剂、药物用膜制剂以及包覆药物固体制剂
CA2839494C (en) * 2011-06-17 2018-11-06 Evonik Roehm Gmbh Coating composition suitable for pharmaceutical or nutraceutical dosage forms
RU2485957C1 (ru) * 2012-03-16 2013-06-27 Государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия последипломного образования" Министерства здравоохранения Российской Федерации (ГБОУ ДПО РМАПО Минздрава России) Средство для лечения низкообменного варианта заболевания скелета у больных с хронической почечной недостаточностью

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE965825C (de) 1949-10-30 1957-06-19 Walter Kloepfer Dipl Ing Dr In Zur Antennenebene senkrecht polarisierter Strahler
US4820698A (en) * 1985-11-04 1989-04-11 The Procter & Gamble Company Antimicrobial agents and process for their manufacture
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5098717A (en) * 1987-12-09 1992-03-24 Thames Pharmacal Co., Inc. Method of treatment for pruritus
PH27186A (en) * 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
EP0550385A1 (de) * 1991-12-19 1993-07-07 Ciba-Geigy Ag Peroral zu verabreichende pharmazeutische Zusammensetzungen, die Methandiphosphonsäure-Derivate und 18-Krone-6 Ether enthalten
TW237386B (enExample) * 1992-04-15 1995-01-01 Ciba Geigy
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
RU2134103C1 (ru) * 1993-05-15 1999-08-10 Берингер Маннхайм ГмбХ Таблетка с улучшенной биодоступностью биологически активного вещества и вещество, повышающее биодоступность
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
DE19615812A1 (de) 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
US5803321A (en) * 1996-11-12 1998-09-08 Randy Hangers, Lll Hanger with ganging element
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery

Also Published As

Publication number Publication date
TR199802108T2 (xx) 1999-01-18
NO319162B1 (no) 2005-06-27
BR9708785A (pt) 1999-08-03
JP5557989B2 (ja) 2014-07-23
PL191363B1 (pl) 2006-05-31
ES2313735T5 (es) 2012-12-07
ES2313735T3 (es) 2009-03-01
CZ297341B6 (cs) 2006-11-15
PT936913E (pt) 2008-09-25
WO1997039755A1 (de) 1997-10-30
HU228389B1 (en) 2013-03-28
HUP9903407A2 (hu) 2000-04-28
JP2000508673A (ja) 2000-07-11
CN101152160A (zh) 2008-04-02
NO984881L (no) 1998-10-19
RU2193881C2 (ru) 2002-12-10
AU2638297A (en) 1997-11-12
PA8427301A1 (es) 2002-07-30
AR054350A2 (es) 2007-06-20
JP2008285500A (ja) 2008-11-27
CA2251886C (en) 2008-06-17
EP0936913A1 (de) 1999-08-25
SI0936913T2 (sl) 2012-11-30
EP1658852B1 (de) 2016-11-09
HUP9903407A3 (en) 2000-11-28
AR006652A1 (es) 1999-09-08
DE19615812A1 (de) 1997-10-23
ZA973331B (en) 1998-10-19
NO984881D0 (no) 1998-10-19
AU722516B2 (en) 2000-08-03
JP5037746B2 (ja) 2012-10-03
EP0936913B2 (de) 2012-09-19
IL163930A0 (en) 2005-12-18
IL126655A0 (en) 1999-08-17
PL329347A1 (en) 1999-03-29
US6143326A (en) 2000-11-07
CO4820394A1 (es) 1999-07-28
ATE404207T1 (de) 2008-08-15
IL126655A (en) 2004-12-15
PL191910B1 (pl) 2006-07-31
CA2251886A1 (en) 1997-10-30
EP1658852A1 (de) 2006-05-24
EP0936913B1 (de) 2008-08-13
CZ336498A3 (cs) 2000-01-12
US20050089573A1 (en) 2005-04-28
DK0936913T3 (da) 2008-10-20
NZ332314A (en) 2000-03-27
SI0936913T1 (sl) 2008-12-31
DE59712959D1 (de) 2008-09-25

Similar Documents

Publication Publication Date Title
DK0936913T4 (da) Oralt farmaceutisk præparat indeholdende ibandronat
ATE206924T1 (de) Oral anzuwendende arzneizubereitung enthaltend olanzapin
DE69916922D1 (de) Ibuprofenhaltige Arzneizubereitung
FI963984L (fi) Uusi oraalinen farmaseuttinen annostelumuoto
EE200000395A (et) Peroraalne farmatseutiline pulseeriva vabanemisega annusvorm
BR9610153A (pt) Formulações farmacêuticas
EE200000383A (et) Peroraalne farmatseutiline pikendatud vabanemisega annusvorm
DE69822172D1 (de) Levosimendanhaltige oral anzuwendende arzneizusammensetzungen
ITMI982222A0 (it) Composizioni farmaceutiche orali contenenti buprenorfina
DE69807768D1 (de) Rapamycin enthaltende Formulierungen zur oralen Verabreichung
EE9800400A (et) Diklofenaaki sisaldavad farmatseutilised kompositsioonid
DE69827947T2 (de) Rapamycin-formulierungen zur oralen verabreichung
DE69812962D1 (de) Oral anzuwendende Arzneizubereitung enthaltend S-(3-Hydroxypropyl)-L-Cystein
FI951155A7 (fi) Farmaseuttinen valmiste
BR9603673A (pt) Preparado de combinação farmacêutica compreendendo cetoprofeno
NO20003284D0 (no) Farmasøytisk preparat for oral administrering
ATA77096A (de) Pharmazeutische präparation
SK1380U (sk) Farmaceutický preparát
SE9402925D0 (sv) Novel oral pharmaceutical composition
FI3862U1 (fi) Geelimuotoinen farmaseuttinen valmiste
IT1288113B1 (it) Composizioni farmaceutiche effervescenti contenenti sobrerolo
IT1284509B1 (it) Composizioni farmaceutiche effervescenti contenenti metansolfoanilidi
SE9402433D0 (sv) New oral pharmaceutical dosage form
GB9711046D0 (en) Oral pharmaceutical compositions